Prelude Therapeutics Incorporated
PRLD
$3.94
$0.102.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -10.39M | -16.46M | -19.73M | -31.23M | -32.09M |
| Total Depreciation and Amortization | 391.00K | 418.00K | 425.00K | 433.00K | 435.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.00M | 2.04M | 2.76M | 3.98M | 4.30M |
| Change in Net Operating Assets | -13.69M | 37.12M | -2.57M | 739.00K | -6.88M |
| Cash from Operations | -21.69M | 23.12M | -19.12M | -26.08M | -34.23M |
| Capital Expenditure | -- | 0.00 | 0.00 | -20.00K | -47.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 8.50M | -60.34M | 40.09M | 11.54M | 62.23M |
| Cash from Investing | 8.50M | -60.34M | 40.09M | 11.52M | 62.19M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00 | 0.00 | -53.00K | -155.00K |
| Issuance of Common Stock | 31.00K | 24.95M | 0.00 | 92.00K | -- |
| Repurchase of Common Stock | -51.00K | -5.00K | -5.00K | -2.00K | -5.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -294.00K | -- | -- | -- | -- |
| Cash from Financing | -314.00K | 24.94M | -5.00K | 37.00K | -160.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.50M | -12.28M | 20.97M | -14.52M | 27.80M |